Filtered By:
Procedure: Hemodialysis
Therapy: Dialysis
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 299 results found since Jan 2013.
Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
Front Biosci (Schol Ed). 2022 Jul 21;14(3):21. doi: 10.31083/j.fbs1403021.ABSTRACTThe most frequent arrhythmia treated is atrial fibrillation (AF), which necessitates the use of oral anticoagulants (OACs) to reduce the risk of thromboembolism and stroke. Patients with chronic kidney disease are more likely to develop AF, with a 10% frequency among those on chronic dialysis. Warfarin is the most widely prescribed OAC for individuals with end-stage kidney disease (ESKD). On the other hand, direct OACs (DOACs) are generally safer than warfarin, with fewer fatal bleeding events and a fixed dose that does not require close inte...
Source: Frontiers in Bioscience - Scholar - September 22, 2022 Category: Biomedical Science Authors: Nikolaos Ktenopoulos Marios Sagris Panagiotis Theofilis Sophia Lionaki Loukianos S Rallidis Source Type: research
The Effects of Mineralocorticoid Receptor Antagonists on Cardiovascular Outcomes in Patients With End ‐Stage Renal Disease and Heart Failure
ConclusionsIn patients undergoing regular dialysis who are diagnosed with heart failure, the use of MRAs is associated with lower risks of all-cause mortality and CV death. The benefits of MRA treatment in heart failure may persist in patients with ESRD. Further investigations through randomized controlled trials are needed to assess the efficacy and safety of MRAs in this high-risk population.This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - November 21, 2022 Category: Cardiology Authors: Donna Shu ‐Han Lin,
Fang‐Ju Irene Lin,
Yu‐Sheng Lin,
Jen‐Kuang Lee,
Yen‐Hung Lin Tags: Research Article Source Type: research
Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
Front Biosci (Schol Ed). 2022 Jul 21;14(3):21. doi: 10.31083/j.fbs1403021.ABSTRACTThe most frequent arrhythmia treated is atrial fibrillation (AF), which necessitates the use of oral anticoagulants (OACs) to reduce the risk of thromboembolism and stroke. Patients with chronic kidney disease are more likely to develop AF, with a 10% frequency among those on chronic dialysis. Warfarin is the most widely prescribed OAC for individuals with end-stage kidney disease (ESKD). On the other hand, direct OACs (DOACs) are generally safer than warfarin, with fewer fatal bleeding events and a fixed dose that does not require close inte...
Source: Frontiers in Bioscience - Scholar - September 22, 2022 Category: Biomedical Science Authors: Nikolaos Ktenopoulos Marios Sagris Panagiotis Theofilis Sophia Lionaki Loukianos S Rallidis Source Type: research
